Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PIK3CA act mut |
| Therapy | Buparlisib + WEHI-539 |
| Indication/Tumor Type | breast cancer |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA act mut | breast cancer | no benefit | Buparlisib + WEHI-539 | Preclinical - Cell culture | Actionable | In a preclinical study, Buparlisib (BKM120) did not sensitize breast cancer cell lines harboring PIK3CA activating mutations to WEHI-539 in culture (PMID: 27974663). | 27974663 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (27974663) | PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation. | Full reference... |